Vutrisiran

Brand names: Amvuttra · Active ingredient: Vutrisiran Sodium

In short: AMVUTTRA is indicated for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis (hATTR-PN) in adults. AMVUTTRA is indicated for the treatment of the cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis (ATTR-CM) in adults to reduce cardiovascula

Forms & strengthsInjection: 25 mg/0.5 mL of vutrisiran as a clear, colorless-to-yellow solution in a single-dose prefilled syringe.
LabelAlnylam Pharmaceuticals, Inc.
Label updatedNov 17, 2025

What is Vutrisiran used for?

AMVUTTRA is indicated for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis (hATTR-PN) in adults.

AMVUTTRA is indicated for the treatment of the cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis (ATTR-CM) in adults to reduce cardiovascular mortality, cardiovascular hospitalizations and urgent heart failure visits.

Vutrisiran dosage

The recommended dosage of AMVUTTRA is 25 mg administered by subcutaneous injection once every 3 months .

Missed Dose

If a dose is missed, administer AMVUTTRA as soon as possible. Resume dosing every 3 months from the most recently administered dose.

AMVUTTRA is for subcutaneous use only and should be administered by a healthcare professional.

Syringe Appearance Before and After Use

Before Use | After Use

Preparation and Administration

1.

Prepare the syringe

If stored cold, allow the syringe to warm to room temperature for 30 minutes prior to use.Remove the syringe from the packaging by gripping the syringe body.

Do not touch the plunger rod until ready to inject.

Visually inspect the drug solution for discoloration and particulate matter prior to administration. AMVUTTRA is a sterile, preservative-free, clear, colorless-to-yellow solution. Do not use if it contains particulate matter or if it is cloudy or discolored.Check the following:

Syringe is not damaged, such as cracked or leaking

Needle cap is attached to the syringe

Expiration date on syringe label

Do not use the syringe if any issues are found while checking the syringe.

2.

Choose and prepare the injection site

Choose an injection site from the following areas: the abdomen, thighs, or upper arms.Avoid the following:

5-cm area around the navel

Scar tissue or areas that are reddened, inflamed, or swollen

Clean the chosen injection site.

3.

Prepare the syringe for injection

Hold the syringe body with one hand. Pull the needle cap straight off with other hand and dispose of needle cap immediately. It is normal to see a drop of liquid at the tip of the needle.

Do not touch the needle or let it touch any surface.

Do not recap the syringe.

Do not use the syringe if it is dropped.

4.

Perform the injection

Pinch the cleaned skin.Fully insert the needle into the pinched skin at a 45°-90° angle.

Inject all of the medication.

Push the plunger rod as far as it will go to administer the dose and activate the needle shield.

Release the plunger rod to allow the needle shield to cover the needle.

Do not block plunger rod movement.

5.

Dispose of the syringe

Immediately dispose of the used syringe into a sharps container.

How to take Vutrisiran — instructions & advice from the label

Recommended Vitamin A Supplementation

Inform patients that AMVUTTRA treatment leads to a decrease in serum vitamin A levels. Instruct patients to take the recommended daily allowance of vitamin A. Advise patients to contact their healthcare provider if they experience ocular symptoms suggestive of vitamin A deficiency (e.g., night blindness) and refer them to an ophthalmologist if they develop these symptoms .

Pregnancy

Instruct patients that if they are pregnant or plan to become pregnant while taking AMVUTTRA they should inform their healthcare provider. Inform patients of the potential risk to the fetus, including that AMVUTTRA treatment leads to a decrease in serum vitamin A levels .

Warnings & precautions

Do not take this medicine if: None.

AMVUTTRA treatment leads to a decrease in serum vitamin A levels .

Supplementation at the recommended daily allowance of vitamin A is advised for patients taking AMVUTTRA. Higher doses than the recommended daily allowance of vitamin A should not be given to try to achieve normal serum vitamin A levels during treatment with AMVUTTRA, as serum vitamin A levels do not reflect the total vitamin A in the body.

Patients should be referred to an ophthalmologist if they develop ocular symptoms suggestive of vitamin A deficiency (e.g., night blindness).

Vutrisiran side effects

The following clinically significant adverse reactions are discussed in greater detail in other sections of the labeling:

Reduced Serum Vitamin A Levels and Recommended Supplementation

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of AMVUTTRA cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

Two Phase 3 randomized, multi-center studies evaluated the safety of AMVUTTRA in 448 transthyretin-mediated amyloidosis (ATTR) patients, including 122 patients with hATTR-PN (HELIOS-A) and 326 patients with ATTR-CM (HELIOS-B) . In both studies, patients were instructed to take the recommended daily allowance of vitamin A .

Polyneuropathy of Hereditary Transthyretin-mediated Amyloidosis

In HELIOS-A, 118 patients received at least 18 months of treatment. The mean duration of treatment was 18.8 months (range: 1.7 to 19.4 months). The median patient age at baseline was 60 years and 65% of the patients were male. Seventy percent of AMVUTTRA-treated patients were Caucasian, 17% were Asian, 3% were Black, and 9% were reported as Other. Forty-four percent of patients had the Val30Met mutation in the transthyretin gene; the remaining patients had one of 21 other mutations. At baseline, 70% of patients were in Stage 1 of the disease and 30% were in Stage 2. …

About this medicine

AMVUTTRA contains vutrisiran, a chemically modified double-stranded small interfering ribonucleic acid (siRNA) that targets mutant and wild-type transthyretin (TTR) messenger RNA (mRNA) and is covalently linked to a ligand containing three N-acetylgalactosamine (GalNAc) residues to enable delivery of the siRNA to hepatocytes.

The structural formula of vutrisiran sodium is presented below.

Dashed lines denote Watson-Crick base pairing

The molecular formula of vutrisiran sodium is C530H672F9N171Na43O323P43S6 with a molecular weight of 17,290 Da. The molecular formula of the free acid is C530H715F9N171O323P43S6 with a molecular weight of 16,345 Da.

AMVUTTRA is supplied as a sterile, preservative-free, clear, colorless-to-yellow solution for subcutaneous injection. Each 0.5 mL of solution contains 25 mg of vutrisiran (equivalent to 26.5 mg vutrisiran sodium), 0.2 mg sodium phosphate monobasic dihydrate, 0.7 mg sodium phosphate dibasic dihydrate, 3.2 mg sodium chloride, water for injection, and sodium hydroxide and/or phosphoric acid to adjust the pH to ~7. …

Disclaimer: This page is for general information only and is not medical advice. It is a condensed summary of the official FDA-approved label — it does not replace the full prescribing information or the advice of your doctor or pharmacist. Always follow your prescriber's instructions and read the medication guide that comes with your medicine.

Source: FDA-approved label via DailyMed (U.S. National Library of Medicine), label set ID 8db0facb-81b6-4006-9239-27dc6409c5d3. Read the full official label on DailyMed.

Related medicines

Rosuvastatin Semaglutide Hydrochlorothiazide Apixaban Simvastatin Empagliflozin Furosemide Carvedilol